SG11202000298VA - Antibodies to madcam - Google Patents
Antibodies to madcamInfo
- Publication number
- SG11202000298VA SG11202000298VA SG11202000298VA SG11202000298VA SG11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA SG 11202000298V A SG11202000298V A SG 11202000298VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- madcam
- international
- disclosure
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo Ho VIII Inv n (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/014572 Al (43) International Publication Date 17 January 2019 (17.01.2019) WIPO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 29/00 (2006.01) A61P 37/06 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2018/042052 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,809 14 July 2017 (14.07.2017) US (71) Applicant: PFIZER, INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventor: ANDERSON, Karin; c/o Pfizer, Inc., 235 East 42nd Street, New York, NY 10017 (US). (74) Agent: MENDEZ, Julio, J. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: ANTIBODIES TO MADCAM (57) : The present disclosure relates to antibodies including human antibodies and antigen- binding portions thereof that specifi- cally bind to MAdCAM, preferably human MAdCAM and that func- tion to inhibit MAdCAM. The disclosure also relates to human an- ti-MAdCAM antibodies and antigen-binding portions thereof. The disclosure also relates to antibodies that are chimeric, bispecific, de- rivatized, single chain antibodies or portions of fusion proteins. The disclosure also relates to isolated heavy and light chain immunoglob- ulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present disclo- sure also relates to methods of making human anti- MAdCAM an- tibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The disclosure also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The disclosure also relates to transgenic animals or plants comprising nu- clpeic acid molecules of the disclosure. Figure IA Figure 1J r Figure IL Figure IB Figure C [MI Figure 10 Figure IF Figure IC A rir.rr. _w,rerrrrri Figure IR Figure IH
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762532809P | 2017-07-14 | 2017-07-14 | |
PCT/US2018/042052 WO2019014572A1 (en) | 2017-07-14 | 2018-07-13 | Antibodies to madcam |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000298VA true SG11202000298VA (en) | 2020-02-27 |
Family
ID=63209653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000298VA SG11202000298VA (en) | 2017-07-14 | 2018-07-13 | Antibodies to madcam |
Country Status (24)
Country | Link |
---|---|
US (2) | US20190169291A1 (en) |
EP (1) | EP3652211A1 (en) |
JP (1) | JP7160491B2 (en) |
KR (1) | KR20200028006A (en) |
CN (1) | CN111032694B (en) |
AR (1) | AR112336A1 (en) |
AU (1) | AU2018300189A1 (en) |
BR (1) | BR112020000698A2 (en) |
CA (1) | CA3069914A1 (en) |
CL (1) | CL2020000102A1 (en) |
CO (1) | CO2020000352A2 (en) |
CR (1) | CR20200076A (en) |
CU (1) | CU20200002A7 (en) |
DO (1) | DOP2020000005A (en) |
EA (1) | EA202090286A1 (en) |
EC (1) | ECSP20011317A (en) |
IL (1) | IL272015A (en) |
MA (1) | MA48241A1 (en) |
NI (1) | NI202000004A (en) |
PE (1) | PE20200616A1 (en) |
PH (1) | PH12020500100A1 (en) |
SG (1) | SG11202000298VA (en) |
TW (1) | TW201920266A (en) |
WO (1) | WO2019014572A1 (en) |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992003917A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International | Homologous recombination in mammalian cells |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
DE69233697T2 (en) | 1991-03-01 | 2008-01-24 | Dyax Corp., Cambridge | Process for the development of binding microproteins |
DE69233750D1 (en) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Libraries of heterodimeric receptors using phagemids |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE4122599C2 (en) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid for screening antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
DK0605522T3 (en) | 1991-09-23 | 2000-01-17 | Medical Res Council | Process for producing humanized antibodies |
JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
WO1993016043A1 (en) | 1992-02-18 | 1993-08-19 | Otsuka Kagaku Kabushiki Kaisha | β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
ATE381614T1 (en) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
AU5675794A (en) | 1992-12-15 | 1994-07-04 | Board Of Trustees Of The Leland Stanford Junior University | Mucosal vascular addressin, dna and expression |
ES2146648T3 (en) | 1993-03-09 | 2000-08-16 | Genzyme Corp | PROCEDURE FOR ISOLATION OF MILK PROTEINS. |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US5698679A (en) | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
US6046037A (en) | 1994-12-30 | 2000-04-04 | Hiatt; Andrew C. | Method for producing immunoglobulins containing protection proteins in plants and their use |
US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
MX9706049A (en) | 1995-02-10 | 1998-02-28 | Leukosite Inc | Mucosal vascular addressins and uses thereof. |
US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
US6091001A (en) | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
EP0826034A4 (en) | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | Generation of large genomic dna deletions |
ES2304786T3 (en) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
AU718138B2 (en) | 1995-08-29 | 2000-04-06 | Kyowa Hakko Kirin Co., Ltd. | Chimeric animal and method for constructing the same |
US6037324A (en) | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP2002505097A (en) | 1998-03-03 | 2002-02-19 | アブジェニックス インク. | CD147 binding molecules as therapeutics |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
IL139129A0 (en) | 1998-05-13 | 2001-11-25 | Genentech Inc | Diagnosis and treatment of hepatic disorders |
US7090845B2 (en) | 1998-05-13 | 2006-08-15 | Genentech, Inc. | Diagnosis and treatment of hepatic disorders |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
KR100856446B1 (en) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Human monoclonal antibodies to ctla-4 |
AU7084500A (en) | 1999-09-03 | 2001-04-10 | Human Genome Sciences, Inc. | Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
JP2003089656A (en) | 2001-09-19 | 2003-03-28 | Nippon Kayaku Co Ltd | Inhibitory agent against immune response caused by transplantation |
PT1441589E (en) | 2001-11-08 | 2012-08-13 | Abbott Biotherapeutics Corp | Stable liquid pharmaceutical formulation of igg antibodies |
AR039067A1 (en) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
PT2336184E (en) | 2002-02-25 | 2015-03-09 | Biogen Idec Inc | Administration of agents for the treatment of inflammation |
US20070202097A1 (en) | 2003-03-10 | 2007-08-30 | Krissansen Geoffrey W | Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof |
BRPI0403964B8 (en) | 2003-04-04 | 2021-05-25 | Genentech Inc | stable liquid formulations, article of manufacture and use of these formulations for the treatment of ige-mediated dysfunction |
SV2006001990A (en) | 2004-01-09 | 2006-01-30 | Pfizer | ANTIBODIES AGAINST MADCAM |
WO2005076843A2 (en) | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
CA2600836A1 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
CN101193917A (en) * | 2005-03-08 | 2008-06-04 | 法玛西雅厄普约翰有限责任公司 | Anti-MAdCAM antibody compositions |
CA2613017A1 (en) | 2005-07-08 | 2007-01-18 | Pfizer Limited | Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue |
ATE483732T1 (en) | 2005-07-08 | 2010-10-15 | Pfizer Ltd | MADCAM ANTIBODIES |
EP1904100A1 (en) | 2005-07-11 | 2008-04-02 | Pfizer Limited | New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis |
WO2007007152A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat metastatic cancers and chloroma |
WO2007007151A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Use of anti-mad-cam antibody for the treatment of emphysema |
WO2007007159A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat uterine disorders |
WO2007007160A2 (en) | 2005-07-11 | 2007-01-18 | Pfizer Limited | Anti-madcam antibodies to treat fever |
US8081772B2 (en) | 2008-11-20 | 2011-12-20 | Gentex Corporation | Vehicular microphone assembly using fractional power phase normalization |
RU2015145610A (en) | 2013-03-27 | 2017-05-04 | Дженентек, Инк. | APPLICATION OF BIOMARKERS FOR THE EVALUATION OF TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS BY BETA7 INTEGRIN ANTAGONISTS |
CA2916283A1 (en) | 2015-01-09 | 2016-07-09 | Pfizer Inc. | Dosage regimen for madcam antagonists |
-
2018
- 2018-07-13 SG SG11202000298VA patent/SG11202000298VA/en unknown
- 2018-07-13 TW TW107124340A patent/TW201920266A/en unknown
- 2018-07-13 PE PE2020000060A patent/PE20200616A1/en unknown
- 2018-07-13 CA CA3069914A patent/CA3069914A1/en active Pending
- 2018-07-13 WO PCT/US2018/042052 patent/WO2019014572A1/en unknown
- 2018-07-13 BR BR112020000698-0A patent/BR112020000698A2/en not_active IP Right Cessation
- 2018-07-13 JP JP2020501133A patent/JP7160491B2/en active Active
- 2018-07-13 AR ARP180101961 patent/AR112336A1/en unknown
- 2018-07-13 KR KR1020207004168A patent/KR20200028006A/en not_active Application Discontinuation
- 2018-07-13 US US16/035,178 patent/US20190169291A1/en not_active Abandoned
- 2018-07-13 CN CN201880056875.XA patent/CN111032694B/en active Active
- 2018-07-13 CU CU2020000002A patent/CU20200002A7/en unknown
- 2018-07-13 MA MA48241A patent/MA48241A1/en unknown
- 2018-07-13 EA EA202090286A patent/EA202090286A1/en unknown
- 2018-07-13 CR CR20200076A patent/CR20200076A/en unknown
- 2018-07-13 AU AU2018300189A patent/AU2018300189A1/en active Pending
- 2018-07-13 EP EP18755583.4A patent/EP3652211A1/en active Pending
-
2020
- 2020-01-09 DO DO2020000005A patent/DOP2020000005A/en unknown
- 2020-01-13 IL IL272015A patent/IL272015A/en unknown
- 2020-01-13 CL CL2020000102A patent/CL2020000102A1/en unknown
- 2020-01-13 NI NI202000004A patent/NI202000004A/en unknown
- 2020-01-14 CO CONC2020/0000352A patent/CO2020000352A2/en unknown
- 2020-01-14 PH PH12020500100A patent/PH12020500100A1/en unknown
- 2020-02-13 EC ECSENADI202011317A patent/ECSP20011317A/en unknown
-
2021
- 2021-06-04 US US17/338,991 patent/US11802156B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CO2020000352A2 (en) | 2020-04-13 |
CU20200002A7 (en) | 2020-11-30 |
CL2020000102A1 (en) | 2020-10-09 |
TW201920266A (en) | 2019-06-01 |
ECSP20011317A (en) | 2020-12-31 |
JP7160491B2 (en) | 2022-10-25 |
EA202090286A1 (en) | 2020-05-12 |
WO2019014572A1 (en) | 2019-01-17 |
US11802156B2 (en) | 2023-10-31 |
PH12020500100A1 (en) | 2020-09-14 |
BR112020000698A2 (en) | 2020-07-14 |
NI202000004A (en) | 2020-03-30 |
CR20200076A (en) | 2020-06-10 |
KR20200028006A (en) | 2020-03-13 |
DOP2020000005A (en) | 2021-02-15 |
CA3069914A1 (en) | 2019-01-17 |
US20220119521A1 (en) | 2022-04-21 |
US20190169291A1 (en) | 2019-06-06 |
EP3652211A1 (en) | 2020-05-20 |
CN111032694B (en) | 2024-03-08 |
PE20200616A1 (en) | 2020-03-11 |
IL272015A (en) | 2020-02-27 |
MA48241A1 (en) | 2021-03-31 |
CN111032694A (en) | 2020-04-17 |
AR112336A1 (en) | 2019-10-16 |
AU2018300189A1 (en) | 2020-01-30 |
JP2020533953A (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201909941QA (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909499QA (en) | Humanized antigen-binding domains against cd19 and methods of use | |
SG11201809041TA (en) | Compositions and methods for selective protein expression | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201805493YA (en) | Binding members with altered diversity scaffold domains | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201810465RA (en) | Compositions and methods related to engineered fc constructs | |
SG11201906319XA (en) | Compositions and methods for the depletion of cd137+ cells | |
SG11201807279QA (en) | Binding proteins and methods of use thereof | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases |